Genmin Quote - GEN

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

0.03

Bid

0.029

Offer

0.03

Volume

0.00

0.00 Day's Range 0.00

0.027 52 Week Range 0.1725

Market Cap

20.557M

Previous Close

0.03

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

595,730

Shares Outstanding

685,229,436

Dividend Yield

PE Ratio

-1.56

Earnings Per Share (EPS)

-0.02

Revenue

32k

Net Profit

-13.18M

Sector

Metal Mining Services

Industry

Metal Mining Services

Website

genmingroup.com

Headquarters

Perth, Western Australia, Aus

Founded

Genmin Limited is listed in the Metal Mining Services sector of the Australian Stock Exchange with ticker GEN. The last closing price for Genmin was AUD0.03. Over the last year, Genmin shares have traded in a share price range of AUD 0.027 to AUD 0.1725.

Genmin currently has 685,229,436 shares in issue. The market capitalisation of Genmin is AUD20.56 million. Genmin has a price to earnings ratio (PE ratio) of -1.56.

Genmab Files IND for HuMax-TF-ADC

Company Announcement IND for HuMax(R)-TF-ADC submitted to FDA Genmab's first IND submission for antibody-drug conjugate (ADC) product...

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement Genentech and Biogen Idec refused re-hearing in Arzerra patent infringement case COPENHAGEN, Denmark, July 15, 2013...

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Company Announcement First Phase III study with subcutaneous formulation of ofatumumab Ofatumumab to be investigated in new autoimmune...

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Media Release Antibody-drug conjugate (ADC) to be developed for cancer Combines strength of HuMax(R)-TAC with next generation...

Teprotumumab Restarts Clinical Development in New Indication

Company Announcement Teprotumumab (RG1507) to be investigated for new indication River Vision Development Corporation to conduct...

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

Company Announcement Genmab establishes Sponsored Level 1 ADR program Genmab ADRs can be traded on US over-the-counter (OTC) market...

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Company Announcement Median 22.4 month progression free survival in patients treated with ofatumumab plus chlorambucil, an improvement of...

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement Genentech and Biogen Idec have filed for re-hearing in the United States COPENHAGEN, Denmark, May 17, 2013 (GLOBE...

Genmab Announces Financial Results for the First Quarter of 2013

COPENHAGEN, Denmark, May 7, 2013 (GLOBE NEWSWIRE) -- Interim Report First Quarter 2013 Arzerra(r) received approval in Japan Arzerra net...

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined With Bendamustine in Untreated and Relapsed Chronic Lymphocy

Company Announcement 95% overall response rate and 43% complete response rate in patients with previously untreated chronic lymphocytic...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.001	-3.22580645161	0.031	0.032	0.03	200478	0.03056919	DE
4	-0.004	-11.7647058824	0.034	0.034	0.027	426720	0.03030746	DE
12	-0.006	-16.6666666667	0.036	0.048	0.027	595730	0.0361778	DE
26	-0.062	-67.3913043478	0.092	0.105	0.027	675040	0.04615117	DE
52	-0.07	-70	0.1	0.1725	0.027	714390	0.0770263	DE
156	-0.19	-86.3636363636	0.22	0.28	0.027	389445	0.10781522	DE
260	-0.29	-90.625	0.32	0.34	0.027	395369	0.15362267	DE

GEN - Frequently Asked Questions (FAQ)

What is the current Genmin share price?

The current share price of Genmin is AUD 0.03

How many Genmin shares are in issue?

Genmin has 685,229,436 shares in issue

What is the market cap of Genmin?

The market capitalisation of Genmin is AUD 20.56M

What is the 1 year trading range for Genmin share price?

Genmin has traded in the range of AUD 0.027 to AUD 0.1725 during the past year

What is the PE ratio of Genmin?

The price to earnings ratio of Genmin is -1.56

What is the reporting currency for Genmin?

Genmin reports financial results in AUD

What is the latest annual turnover for Genmin?

The latest annual turnover of Genmin is AUD 32k

What is the latest annual profit for Genmin?

The latest annual profit of Genmin is AUD -13.18M

What is the registered address of Genmin?

The registered address for Genmin is LONDON HOUSE, SUITE 3 LEVEL 8, 216 ST GEORGES TERRACE, PERTH, WESTERN AUSTRALIA, 6000

What is the Genmin website address?

The website address for Genmin is genmingroup.com

Which industry sector does Genmin operate in?

Genmin operates in the METAL MINING SERVICES sector

Symbol	Price	Vol.
ECTEnvironmental Clean Technologies Limited	AUD 0.004 (100.00%)	35.94M
BSAOBSA Ltd	AUD 0.002 (100.00%)	40k
HRZOHorizon Minerals Limited	AUD 0.012 (50.00%)	15k
TX3Trinex Minerals Ltd	AUD 0.0015 (50.00%)	1M
RLCReedy Lagoon Corporation Limited	AUD 0.003 (50.00%)	152.48k
PL3OPatagonia Lithium Ltd	AUD 0.001 (-96.00%)	1.35k
4DXO4DMedical Limited	AUD 0.01 (-80.00%)	285k
VSROVoltaic Strategic Resources Ltd	AUD 0.001 (-75.00%)	1.26M
AEVOAvenira Limited	AUD 0.001 (-50.00%)	1.97M
MOMMoab Minerals Ltd	AUD 0.001 (-50.00%)	237.86k
FBRFBR Limited	AUD 0.02 (11.11%)	49.07M
RR1Reach Resources Lld	AUD 0.018 (44.00%)	39.45M
TLSTelstra Corporation Limited	AUD 4.15 (0.12%)	36.83M
ECTEnvironmental Clean Technologies Limited	AUD 0.004 (100.00%)	35.94M
SIGSigma Healthcare Limited	AUD 3.00 (-1.32%)	30.67M

Symbol

Price

Vol.

FBRFBR Limited

AUD 0.02

(11.11%)

49.07M

RR1Reach Resources Lld

AUD 0.018

(44.00%)

39.45M

TLSTelstra Corporation Limited

AUD 4.15

(0.12%)

36.83M

ECTEnvironmental Clean Technologies Limited

AUD 0.004

(100.00%)

35.94M

SIGSigma Healthcare Limited

AUD 3.00

(-1.32%)

30.67M

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Genmin Limited (GEN)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

About Genmin Limited

Ask ADVFN Intelligence (AI)

GEN Latest News

Genmab Files IND for HuMax-TF-ADC

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Teprotumumab Restarts Clinical Development in New Indication

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Announces Financial Results for the First Quarter of 2013

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined With Bendamustine in Untreated and Relapsed Chronic Lymphocy

GEN - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Genmin Limited (GEN) Share Price

Genmin Limited (GEN)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

About Genmin Limited

Ask ADVFN Intelligence (AI)

GEN Latest News

Genmab Files IND for HuMax-TF-ADC

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Teprotumumab Restarts Clinical Development in New Indication

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Announces Financial Results for the First Quarter of 2013

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined With Bendamustine in Untreated and Relapsed Chronic Lymphocy

GEN - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free